Retatrutide, developed by Soma Chems , represents a promising development in body regulation. This unique drug combines GLP-1 receptor agonist function with GIP receptor stimulation , indicating remarkable efficacy in patient data for body loss . Experts believe Retatrutide is expected to offer a different option for patients experiencing weight-re